In summary, in addition to confirmation of RET-positive lung cancer heterogeneous genotypes and immunotypes, we first reported that patients with concurrent TP53 mutations or high TCR repertoire diversity have relatively unfavorable outcomes. The gene discussed is TP53; the disease is lung cancer.